-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 14 Recently, the share price of Huahai Pharmaceutical has shown a downward trend.
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
Figure 1: The review of topiramate tablets by Huahai Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Topiramate tablets are a new type of broad-spectrum anti-epileptic drug, used for monotherapy in patients newly diagnosed with epilepsy or epilepsy patients who have been combined with drugs and are now converted to monotherapy.
It can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
It can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
Figure 2: Sales of Topiramate Tablets
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
com, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
Only Xi'an Janssen Pharmaceuticals (originally developed for real estate) and Actavis have been approved in the market.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
Source: Mi Nei.
com database, NMPA official website
com database, NMPA official website
The review data statistics are as of April 13, if there are any errors or omissions, please correct me.
Medical Network News, April 14 Recently, the share price of Huahai Pharmaceutical has shown a downward trend.
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
Figure 1: The review of topiramate tablets by Huahai Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Topiramate tablets are a new type of broad-spectrum anti-epileptic drug, used for monotherapy in patients newly diagnosed with epilepsy or epilepsy patients who have been combined with drugs and are now converted to monotherapy.
It can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
It can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
Figure 2: Sales of Topiramate Tablets
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
com, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
Only Xi'an Janssen Pharmaceuticals (originally developed for real estate) and Actavis have been approved in the market.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
Source: Mi Nei.
com database, NMPA official website
com database, NMPA official website
The review data statistics are as of April 13, if there are any errors or omissions, please correct me.
Medical Network News, April 14 Recently, the share price of Huahai Pharmaceutical has shown a downward trend.
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
As of press time, the market value is 26.
8 billion yuan.
Earlier, some media called Huahai Pharmaceutical as an investor.
The company said that the news was not bad.
The employee stock ownership plan in 2015 has been sold and it is expected to maintain positive growth throughout the year.
Recently, the company's application for the listing of 4 types of imitations of topiramate tablets has entered the "under review" status.
If it is successfully approved, it will become the first imitation in China.
Can the news bring benefits to the company?
Figure 1: The review of topiramate tablets by Huahai Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Topiramate tablets are a new type of broad-spectrum anti-epileptic drug, used for monotherapy in patients newly diagnosed with epilepsy or epilepsy patients who have been combined with drugs and are now converted to monotherapy.
It can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
Child, child, kidIt can also be used for adults and children aged 2-16 with partial epilepsy.
Additive treatment of seizures.
Figure 2: Sales of Topiramate Tablets
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
Hospital hospital hospitalcom, in 2019, topiramate tablets ranked eighth among the top 10 terminal anti-epileptic drugs for oral administration in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2019 .
The amount is at the level of 100 million yuan.
Only Xi'an Janssen Pharmaceuticals (originally developed for real estate) and Actavis have been approved in the market.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
As Actavis withdrew from the Chinese market in 2014, the market is currently controlled by Xi'an Janssen Pharmaceuticals, and no domestic generic drugs have been approved for the time being.
If Huahai Pharmaceutical is successfully approved, it will become the first domestic imitation, and the monopoly of the original research pharmaceutical company will be broken.
At the same time, whether this good news can boost the company's stock price is also worthy of continued attention.
Source: Mi Nei.
com database, NMPA official website
com database, NMPA official website
The review data statistics are as of April 13, if there are any errors or omissions, please correct me.
